Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report.
| Autor: | Mendes RR; Gastroenterology Department, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal., Figueiredo PC; Gastroenterology Department, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal., Andrade I; Pathology Department, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | GE Portuguese journal of gastroenterology [GE Port J Gastroenterol] 2023 Sep 01; Vol. 31 (4), pp. 278-282. Date of Electronic Publication: 2023 Sep 01 (Print Publication: 2024). |
| DOI: | 10.1159/000533499 |
| Abstrakt: | Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse. Case Presentation: A 47-year-old female with medical history of stage IV follicular non-Hodgkin lymphoma under chemotherapy presented with chronic bloody diarrhea and iron deficiency anemia. Endoscopic and histologic features resembled inflammatory bowel disease (IBD), imposing a thorough differential diagnosis. The diagnosis of obinutuzumab-induced pancolitis was made and the drug was suspended with subsequent clinical improvement. Conclusion: This is the first case report of obinutuzumab-induced pancolitis. The challenging differential diagnosis of IBD required a multidisciplinary approach with subsequent outcome and management implications. Competing Interests: The authors have no conflicts of interest to declare. (© 2023 The Author(s).Published by S. Karger AG, Basel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|